DDInter222 DDInter1233
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Bortezomib {u} (Compound) downregulates {v} (Gene) ADGRE5
ADGRE5 {u} (Gene) is upregulated by {v} (Compound) Mitotane
Bortezomib {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is downregulated by {v} (Compound) Mitotane
Bortezomib {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Mitotane
Bortezomib {u} (Compound) downregulates {v} (Gene) ADGRE5
ADGRE5 {u} (Gene) regulates {v} (Gene) PEG10
PEG10 {u} (Gene) is downregulated by {v} (Compound) Mitotane
Bortezomib {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) regulates {v} (Gene) GJA1
GJA1 {u} (Gene) is downregulated by {v} (Compound) Mitotane
Bortezomib {u} (Compound) causes {v} (Side Effect) Dyspepsia
Dyspepsia {u} (Side Effect) is caused by {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Bortezomib {u} (Compound) upregulates {v} (Gene) KLHL21
KLHL21 {u} (Gene) is upregulated by {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Bortezomib {u} (Compound) downregulates {v} (Gene) SUV39H1
SUV39H1 {u} (Gene) is upregulated by {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Bortezomib {u} (Compound) upregulates {v} (Gene) DFFA
DFFA {u} (Gene) is downregulated by {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Bortezomib (Compound) downregulates ADGRE5 (Gene) and ADGRE5 (Gene) is upregulated by Mitotane (Compound)
Bortezomib (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is downregulated by Mitotane (Compound)
Bortezomib (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Mitotane (Compound)
Bortezomib (Compound) downregulates ADGRE5 (Gene) and ADGRE5 (Gene) regulates PEG10 (Gene) and PEG10 (Gene) is downregulated by Mitotane (Compound)
Bortezomib (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) regulates GJA1 (Gene) and GJA1 (Gene) is downregulated by Mitotane (Compound)
Bortezomib (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)
Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)
Bortezomib (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) is upregulated by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)
Bortezomib (Compound) downregulates SUV39H1 (Gene) and SUV39H1 (Gene) is upregulated by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)
Bortezomib (Compound) upregulates DFFA (Gene) and DFFA (Gene) is downregulated by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)